Achieve Life Sciences/$ACHV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Achieve Life Sciences
Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
- Ticker
- $ACHV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 28
- Headquarters
- Bothell, United States
- Website
- www.achievelifesciences.com
ACHV Metrics
BasicAdvanced
$656M
-
-$1.81
2.25
-
Price and volume
Market cap
$656M
Beta
2.25
52-week high
$8.64
52-week low
$2.62
Average daily volume
1.4M
Financial strength
Current ratio
0.959
Quick ratio
0.948
Long term debt to equity
-0.508
Total debt to equity
-1.019
Interest coverage (TTM)
-42.54%
Profitability
EBITDA (TTM)
-58.053
Management effectiveness
Return on assets (TTM)
-29.21%
Return on equity (TTM)
-844.99%
Valuation
Price to book
-44.62
Price to tangible book (TTM)
-39.64
Price to free cash flow (TTM)
-8.512
Free cash flow yield (TTM)
-11.75%
Free cash flow per share (TTM)
-0.749
Growth
Earnings per share change (TTM)
24.07%
3-year earnings per share growth (CAGR)
-13.13%
What the Analysts think about ACHV
Analyst ratings (Buy, Hold, Sell) for Achieve Life Sciences stock.
Analyst projections of the future price of Achieve Life Sciences stock.
Bulls say / Bears say
The FDA’s refusal was tied to manufacturing compliance and unfinished labelling, not reported efficacy or clinical-safety deficiencies. Achieve has moved production to Adare and says it plans to resubmit in the fourth quarter of 2026. (Reuters, Achieve Life Sciences)
In a year-long study of people who had already failed a supported quit attempt, 31.2% achieved four-week sustained abstinence in the final four weeks of treatment. The study found no new safety signals, adding supportive evidence for longer treatment. (Achieve Life Sciences)
The $180 million upfront private placement and $187.3 million of cash, equivalents and marketable securities at June 2026 give Achieve substantial resources for the regulatory work and launch preparations. It has also transferred testing methods to Adare and made an engineering batch there. (Achieve Life Sciences)
The FDA did not approve cytisinicline on the original review timetable, delaying a potential launch while Achieve addresses manufacturing and labelling issues. The company is targeting approval only in the first half of 2027, and that timetable depends on a successful resubmission. (Reuters, Achieve Life Sciences)
Achieve has no approved products or sales revenue and relies on cytisinicline as its sole product candidate. Its filing also flags dependence on third-party manufacturing and limited plant-source supply, as well as an ongoing dispute with supplier Sopharma. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
ACHV Financial Performance
Revenues and expenses
ACHV Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ACHV
Fund name | Fund size | $ACHV weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.